Voro and Alloy partner on tumour-selective TCE therapeutics

Voro Therapeutics and Alloy Therapeutics have formed a strategic research partnership to develop tumour-selective, next-generation masked TCE therapeutics The new arrangement between Voro and Alloy centres on finding approaches that may enhance the therapeutic index of TCE therapies. The partnership aims to create immunotherapies that trigger immune responses in tumours while limiting effects on healthy tissues. Credit: TheCorgi / Shutterstock.com. Voro Therapeutics and Alloy Therapeutics have formed a strategic research partnership to develop tumour-selective, next-generation masked T-cell engager (TCE) therapeutics. The partnership will bring together Voro Therapeutics’ tumour-activated biologics platform with Alloy Therapeutics’ cluster of differentiation 3 (CD3) antibodies and…

Source: Pharmaceutical Technology